Table 2.
Experimental antibody therapies.
| Class | Drug | ORR | # of patients | Study phase |
|---|---|---|---|---|
| IL-2 fusion protein | E777 | 29% 38% |
17 13 |
Phase I (39) Phase I (40) |
| Anti-CD52 Mab | Alemtuzumab | 52% 51% |
22 39 |
Phase II (42) Retrospective (43) |
| Anti-KIR3DL2 Mab | IPH4102 | 43% | 13 | Phase I (47) |
| Anti-PD-1/PD-L1 Mab | Pembrolizumab Nivolumab |
38% 15% |
24 13 |
Phase II (36) Phase I (38) |
| Anti-CD47 Mab | TTI-621 | Not reported | 9 | Phase I (52) |
| Bispecific CD30-CD16 ab | AFM13 | 44% | 9 | Phase I (55) |
| Anti-CD70 Mab | ARGX-110 | 56% | 16 | Phase I (60) |